Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (continuous data) ‐ blood glucose (mg/dL) on day 7 · critically ill patients
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ suspected or probable pneumonia · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ suspected or probable… compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Adverse events experienced at short or long term ‐ Serious adverse events 24 weeks' · infantile haemangiomas (strawberry birthmarks) of the skin
Oral propranolol showed no clear difference in adverse events experienced at short or long term ‐ Serious adverse… compared with placebo (low certainty).
1 finding from 1 review
Serious or severe adverse events N of participants with positive severe adverse events · people with acne scars
It is very uncertain whether chemical peeling changes serious or severe adverse events N of participants with positive… compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events a. Serious adverse events b. Discontinuation of trial because of adverse events · obese children and adolescents
The intervention showed no clear difference in adverse events a. Serious adverse events b. Discontinuation of trial… (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether mood stabilisers changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (such as donor site morbidity, failure of graft including re‐rupture) at 2 years · Adults with acute anterior cruciate ligament (ACL) injuries (young, active individuals)
1 finding from 1 review
Adverse effects: at least one serious adverse event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Palliative care showed no clear difference in serious adverse events Assessed by: number of participants… compared with usual care (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low
Adverse events experienced at short or long term ‐ Serious cardiovascular adverse events ‐ bradycardia 24 weeks' · infantile haemangiomas (strawberry birthmarks) of the skin
1 finding from 1 review
Adverse events: treatment failure (non response, serious infection, persistently elevated creatinine) at 6 months · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor probably leads to lower adverse events: treatment failure at 6 months (non response, serious… compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review